Search Result

Results for "

t1/2

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (1) Acyltransferase (1) ADC Linker (1) Adenosine Receptor (1) Adrenergic Receptor (1) Apoptosis (2) Bacterial (1) Bcl-2 Family (3) Casein Kinase (1) CXCR (1) Endogenous Metabolite (5) FXR (1) Hedgehog (2) Histone Methyltransferase (2) HIV (2) HSP (2) LPL Receptor (1) Microtubule/Tubulin (1) MMP (1) Molecular Glues (1) mTOR (1) NOD-like Receptor (NLR) (2) Parasite (1) Phosphatase (1) Phosphodiesterase (PDE) (2) PPAR (3) Protease Activated Receptor (PAR) (2) SARS-CoV (1) SHP2 (1) TAM Receptor (1) Tau Protein (1) Virus Protease (1)
By Research Areas:	Cancer (21) Cardiovascular Disease (1) Infection (5) Inflammation/Immunology (9) Metabolic Disease (4) Neurological Disease (7)

By Targets:

5-HT Receptor (1)

Acyltransferase (1)

ADC Linker (1)

Adenosine Receptor (1)

Adrenergic Receptor (1)

Apoptosis (2)

Bacterial (1)

Bcl-2 Family (3)

Casein Kinase (1)

CXCR (1)

Endogenous Metabolite (5)

FXR (1)

Hedgehog (2)

Histone Methyltransferase (2)

HIV (2)

HSP (2)

LPL Receptor (1)

Microtubule/Tubulin (1)

MMP (1)

Molecular Glues (1)

mTOR (1)

NOD-like Receptor (NLR) (2)

Parasite (1)

Phosphatase (1)

Phosphodiesterase (PDE) (2)

PPAR (3)

Protease Activated Receptor (PAR) (2)

SARS-CoV (1)

SHP2 (1)

TAM Receptor (1)

Tau Protein (1)

Virus Protease (1)

By Research Areas:

Cancer (21)

Cardiovascular Disease (1)

Infection (5)

Inflammation/Immunology (9)

Metabolic Disease (4)

Neurological Disease (7)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-118770

Nafetolol K 5407 free base	Adrenergic Receptor	Cardiovascular Disease
Nafetolol (K 5407), specifically effective on cardiac (β1)-adrenoceptors, is an orally active β blocking agent, with a t_1/2 of ~ 2 h in dogs ^[1].

HY-153822

JG-23	Tau Protein	Neurological Disease
JG-23 is a 4-chloro modified analog with ability to promote t-tau degradation. JG-23 exhibits good metabolic stability with a long T1/2 value (36 min) in mouse liver microsome assays ^[1].

HY-162655

SLF80821178	Others	Neurological Disease
SLF80821178 is a potent and orally active inhibitor of Sphingosine-1-Phosphate Transporter (Spns2). SLF80821178 inhibits S1P release with an IC₅₀ of 51 nM in HeLa cells and a T_1/2 of 2.4 h in mouse ^[1].

HY-145362

S1P1 agonist 4	LPL Receptor	Others
S1P1 agonist 4 has a better profile in both potency (EC₅₀ < 0.05 mg/kg) and predicted human half-life (t1/2 ∼ 5 days).

HY-16309

MB-07803	Phosphatase	Metabolic Disease
MB07803 is an orally available prodrug of a potent, noncompetitive inhibitor (MB07729) of fructose 1,6-bisphosphatase (FBPase), with EC₅₀ of 140 nM and *t_1/2* of 7.6±2.9 h.

HY-P10219

Brevicidine analog 22	Bacterial	Infection Inflammation/Immunology
Brevicidine analog 22 (22) exerts broad spectrum antimicrobial activity and excellent stability (t_1/2 = 40.98 h), with MICs of 2-16 μM for gram-negative and gram-positive bacteria ^[1].

HY-113567

GSK2324	FXR	Metabolic Disease
GSK2324 (Compd 1c) is a FXR agonist for diabetes study, with an EC₅₀ of 120 nM. GSK2324 exhibits t_1/2 values of 84 min (mouse), 170 min (rat), 110 min (beagle) and 120 min (cyno), respectively ^[1].

HY-100866B

F1324 acetate	Bcl-2 Family	Cancer
F1324 acetate is a potent, high affinity peptidic inhibitor of B cell lymphoma 6 (BCL6), with an IC₅₀ of 1 nM. F1324 acetate exhibits binding t_1/2 value of 441 s and has strong inhibition activity against BCL6 PPI ^[1].

HY-100866

F1324	Bcl-2 Family	Cancer
F1324 is a potent, high affinity peptidic inhibitor of B cell lymphoma 6 (BCL6) with an IC₅₀ of 1 nM. F1324 exhibits binding t_1/2 value of 441 s and has strong inhibition activity against BCL6 PPI ^[1].

HY-139721

Tenofovir-C3-O-C15-CF3 ammonium	HIV	Infection
Tenofovir-C3-O-C15-CF3 (ammonium) exhibits substantially longer t1/2 values than tenofovir in human liver microsomes, potent anti-HIV activity in vitro, and enhances pharmacokinetic properties in vivo.

HY-100866A

F1324 TFA	Bcl-2 Family	Cancer
F1324 TFA is a potent, high affinity peptidic inhibitor of B cell lymphoma 6 (BCL6), with an IC₅₀ of 1 nM. F1324 TFA exhibits binding t_1/2 value of 441 s and has strong inhibition activity against BCL6 PPI ^[1].

HY-162406

UNC8969	TAM Receptor	Cancer
UNC8969 (compound 43) is a MERTK/AXL dual inhibitor with IC₅₀s of 1.1±0.8 nM for MERTK and 5.3 ± 2.7 nM for AXL. UNC8969 also exerts a *T_1/2* of 7.3 h with 5 mg/kg i.v. in mice ^[1].

HY-159489

SDUY038	SHP2	Cancer
SDUY038 is a SHP2 allosteric inhibitor, with an IC₅₀ of 1.2 μM and K_D of 0.29 μM, respectively. SDUY038 exhibits pan-antitumor activity (IC₅₀ = 7-24 μM) by suppressing pERK expression. SDUY038 exhibits t_1/2 of 3.95 h by oral administration ^[1].

HY-128947

CL2 Linker	ADC Linker	Cancer
CL2 Linker is a cleavableADC linker. CL2-SN-38 and CL2A-SN-38 are equivalent in agent substitution (~6), cell binding (K_d ~1.2 nM), cytotoxicity (IC₅₀ ~2.2 nM), and serum stability in vitro (t_1/2 ~20 hours) ^[1] .

HY-146054

CXCR4 modulator-2	CXCR	Inflammation/Immunology
CXCR4 modulator-2 (compound Z7R) is a highly potent CXCR4 modulator with an IC₅₀ value of 1.25 nM. CXCR4 modulator-2 has acceptable stability (t_1/2 = 77.1 min) in mouse serum and exhibits anti-inflammatory activity in mouse edema model ^[1].

HY-162408

PAR4 antagonist 3	Protease Activated Receptor (PAR)	Others
PAR4 antagonist 3 (Compound 36) is a selective antagonist for protease activated receptor 4 (PAR4). PAR4 antagonist 3 exhibits antiplatelet efficacy with IC₅₀ of 26.1 nM. PAR4 antagonist 3 improves metabolic stablility in human liver microsomes with T_1/2 of 97.6 min ^[1].

HY-162409

PAR4 antagonist 4	Protease Activated Receptor (PAR)	Others
PAR4 antagonist 4 (Compound 37) is a selective antagonist for protease activated receptor 4 (PAR4). PAR4 antagonist 3 exhibits antiplatelet efficacy with IC₅₀ of 14.2 nM. PAR4 antagonist 3 improves metabolic stablility in human liver microsomes with T_1/2 of 42.5 min ^[1].

HY-158090

Triptolide palmitate	Others	Cancer
Triptolide palmitate is the derivative of Triptolide (HY-32735). Triptolide palmitate exhibits cytotoxicity against cancer cell MCF-7 and A549, with IC₅₀ of 7.5 and 6.4 μM. Triptolide palmitate exhibits a half-time T_1/2 of 50.4 min in Sprague Dawley rats. Triptolide palmitate can be utilizd as drug carrier ^[1].

HY-118717

mTOR inhibitor WYE-28	mTOR	Cancer
mTOR inhibitor WYE-28 (compound 28) is a selective inhibitor of mTOR>/b< (IC₅₀)=0.08 nM. mTOR inhibitor WYE-28 inhibits PI3Kα** with an IC50 value of 6 nM. mTOR inhibitor WYE-28 shows a metabolic time (T_1/2) in nude mouse microsomes of 13 min ^[1].**

HY-155687

PDE5-IN-10	Phosphodiesterase (PDE)	Neurological Disease
PDE5-IN-10 (compound 4b) is a potent PDE5 inhibitor with an IC₅₀ of 20 nM. PDE5-IN-10 improves in vitro microsomal stability (t_1/2 = 44.6 min) as well as excellent efficacy in restoring long-term potentiation. PDE5-IN-10 can be used for Alzheimer’s disease (AD) research ^[1].

HY-146594

NLRP3-IN-8	NOD-like Receptor (NLR)	Inflammation/Immunology
NLRP3-IN-8 (compound 27) is an orally active, directly binding NLRP3 inflammasome inhibitor with an IC₅₀ value of 1.23 μM against IL-1 β. NLRP3-IN-8 has good metabolic stability to liver microsomes (t_1/2 = 138.63 min), and has almost no toxicity (against L02: IC₅₀ > 100 μM) ^[1].

HY-15990

CH5164840	HSP	Cancer
CH5164840 (16) shows high binding affinity for N-terminal Hsp90a (K_d = 0.52 nM) and strong anti-proliferative activity against human cancer cell lines (HCT116 IC₅₀ = 0.15 μM, NCI-N87 IC₅₀ = 0.066 μM). CH5164840 (16) is orally active (t_1/2 = 2.64 h) with potent antitumor efficacy ^[1].

HY-139722

Tenofovir-C3-O-C12-trimethylsilylacetylene ammonium	HIV	Infection
Tenofovir-C3-O-C12-trimethylsilylacetylene (ammonium) exhibits substantially longer t1/2 values than tenofovir in human liver microsomes, potent anti-HIV activity in vitro, and enhances pharmacokinetic properties in vivo. Tenofovir-C3-O-C12-trimethylsilylacetylene (ammonium) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-146034

NOD1/2 antagonist-1	NOD-like Receptor (NLR)	Inflammation/Immunology Cancer
NOD1/2 antagonist-1 (compound 36b) is a potent *NOD1/2* (nucleotide-binding oligomerization domain-like receptor 1/2) dual antagonist, with IC₅₀ values of 1.13 (NOD1) and 0.77 μM (NOD2), respectively. NOD1/2 antagonist-1 has a acceptable T_1/2 (67.6 min). NOD1/2 antagonist-1 (compound 36b) can improve the antitumor efficacy of Paclitaxel (PTX) ^[1].

HY-148571

TP0597850	MMP	Inflammation/Immunology Cancer
TP0597850 is a selective inhibitor of MMP2 (IC₅₀=0.22 nM). TP0597850 has a long MMP2 dissociation half-life (t_1/2=265 min) .

HY-157334

DEG-77	Molecular Glues Casein Kinase	Cancer
DEG-77, a IKZF2 and CK1α targeted molecular glue, possesses suitable pharmacokinetic properties, solubility, and selectivity for in vivo studies (t_1/2=8h) .

HY-155051

Antiproliferative agent-25	Apoptosis Histone Methyltransferase	Cancer
Antiproliferative agent-25 (Compound 3s4) is a selective PRMT5 inhibitor (IC₅₀: 0.11 μM). Antiproliferative agent-25 up-regulates hnRNP E1 protein level. Antiproliferative agent-25 forms H-bond interactions with SAM and E444 residue of PRMT5. Antiproliferative agent-25 has antiproliferative effects against A549 cells by inducing apoptosis and inhibiting cell migration. Antiproliferative agent-25 has high clearances with T_1/2 of only 21.8 and 4.7 min in human and rat liver microsomes ^[1].

HY-162484

GZNL-P36	SARS-CoV Virus Protease	Infection
GZNL-P36 is an orally active inhibitor for SARS-CoV-2 papain-like protease (PL ^pro), with an IC₅₀ of 6.45 nM. GZNL-P36 inhibits SARS-CoV and its variants with EC₅₀ range from 58.2 nM to 2.66 μM. GZNL-P36 exhibits a peak plasma concentration C_max of 549 ng/mL, a half-life T_1/2 of 1.45 h and a bioavailability of 74.7% in CD-1 mouse. GZNL-P36 exhibits antiviral activity in SARS-CoV-2 XXB.1 infection in mouse ^[1].

HY-155050

PRMT5-IN-31	Apoptosis Histone Methyltransferase	Cancer
PRMT5-IN-31 (Compound 3m) is a selective PRMT5 inhibitor (IC₅₀: 0.31 μM). PRMT5-IN-31 up-regulates hnRNP E1 protein level. PRMT5-IN-31 occupies the substrate site of PRMT5 and forms essential interactions with amino acid residues. PRMT5-IN-31 has antiproliferative effects against A549 cells by inducing apoptosis and inhibiting cell migration. PRMT5-IN-31 has high metabolic stability on human liver microsomes (T_1/2: 132.4 min) ^[1].

HY-N12728

Heteroclitin G	Others	Others
Heteroclitin G is a lignan which can be extracted from Dian-Jixueteng. Heteroclitin G (2.0 mg/kg, i.v.) exerts an C_5min of 665.97 ± 29.89 ng/mL and T_1/2z of 5.04 ± 1.84 h ^[1].

HY-149920

Anticancer agent 98	Microtubule/Tubulin	Cancer
Anticancer agent 98 (compound 12k) is a microtubule/tubulin-polymerization inhibitor (K_d=16.9 μM). Anticancer agent 98 exerts antiproliferative potency against tumor cells, exhibits anti-angiogenesis effect in vitro. Anticancer agent 98 exhibits good human and mouse liver microsomes stability with both t_1/2>300 min ^[1].

HY-155354

Antimalarial agent 33	Parasite	Infection
Antimalarial agent 33 (compound 5g) has antiplasmodial activity against erythrocytic and hepatic stages of Plasmodium with an EC₅₀ of 1.1 μM for K1 P. falciparum strain. Antimalarial agent 33 demonstrats enhanced microsomal stability (T_1/2=29 min). Antimalarial agent 33 has no significant cytotoxicity against primary hepatocytes .

HY-149663

BMS-986172	Acyltransferase	Metabolic Disease
BMS-986172 is an orally active, highly selective MGAT2 inhibitor with an IC₅₀ of 4.6 nM and 20 nM for hMGAT2 and mMGAT2, respectively. BMS-986172 has a T_1/2>120 min in vitro assays. BMS-986172 reduces food intake and body weight. BMS-986172 has the potential for metabolic disorders such as obesity and NASH research .

HY-N6720

T-2 Triol	Endogenous Metabolite	Metabolic Disease
T-2 Triol is a trichothecene mycotoxin derived by the metabolism of T-2 toxin. It is less toxic than T-2 toxin ^[1]. T-2 Triol major metabolites are evaluated in broiler chickens with Half-lives (t_1/2λz), Peak plasma concentrations (C_max) and T_max values of 9.6 mins, 563 ng/ml , 2.5 mins, respectively .

HY-162583

PDE4-IN-17	Phosphodiesterase (PDE)	Inflammation/Immunology
PDE4-IN-17 (compound 4e) is a potent PDE4 inhibitor. PDE4-IN-17 inhibits PDE4B and PDE4D with IC₅₀s of 10.0 and 15.2 nM, respectively. PDE4-IN-17 has good oral bioavailability (F=66%) and longer half-life (t_1/2=2.0 h) in SD rats .

HY-163345

5-HT7R antagonist 2

5-HT Receptor

Neurological Disease

5-HT7R antagonist 2 (compound 4h) is a 5-HT7R antagonist that antagonizes the G protein and β-arrestin signaling pathways, with a K_i of 67 nM, the IC₅₀ values in cAMP and Tango tests were 2.59 μM and 39.57 μM, respectively. 5-HT7R antagonist 2 has an effect on neurogenesis and can reduce repetitive behaviors related to autism spectrum disorder (ASD) and restore neurogenesis of ASD impairment ^[1].
Pharmacokinetic Analysis ICR Male Mice ^[1]

药代动力学分析 ^[1]

Plasma	Intravenous Administration	Intraperitoneal Administration
T_max (h)	0.08	0.25
T_1/2 (h)	0.77	1.06
C_max (ng/mL)	33.07	156.44
AUC_last (ng·h/mL)	28.31	143.27
CL (L/h/kg)	41.61	-
V_ss (L/kg)	32.43	-
MRT (h)	0.79	0.93
F (%)	50.60

HY-149916

A2AR-antagonist-1	Adenosine Receptor	Cancer
A2AR-antagonist-1 (compound 38) is an orally active adenosine A2A receptor (A2AR) antagonist (IC₅₀=29 nM). A2AR-antagonist-1 exhibits anti-tumor activity and mouse liver microsomal metabolic stability (t_1/2=86.1 min). A2AR-antagonist-1 is also a T cells activator, via inhibiting immunosuppressive molecules (LAG-3 and TIM-3) and enhancing effector molecules (GZMB, IFNG, and IL-2) .

HY-113338A

8-Hydroxyguanine hydrochloride	Endogenous Metabolite	Others
8-Hydroxyguanine hydrochloride is a DNA damage product under oxidative stress, which is formed when hydroxyl radicals attack guanine in DNA. 8-Hydroxyguanine hydrochloride induces mutagenesis and leads to a transversion from G to T .

HY-153456

Hedgehog IN-2	Hedgehog	Cancer
Hedgehog IN-2 (Compound 20) is an inhibitor of Hedgehog pathway with an IC₅₀ value less than 0.003 μM in C3H10T1/2 cells ^[1].

HY-143400

HSP70-IN-3	HSP Hedgehog	Cancer
HSP70-IN-3 is a potent HSP70 inhibitor (IC₅₀s of 1.1 and 1.9 μM in ASZ001 and C3H10T1/2, respectively). HSP70-IN-3 has anti-Hh (Hedgehog signaling) activity and anti-proliferative activity and reduces expression of the oncogenic transcription factor GLI1 ^[1].

HY-108568

15-Deoxy-Δ-12,14-prostaglandin J2 1 Publications Verification 15d-PGJ2; 15-Deoxy-Δ12,14-PGJ2	PPAR Endogenous Metabolite	Neurological Disease Inflammation/Immunology Cancer
15-Deoxy-Δ-12,14-prostaglandin J2 (15d-PGJ2) is a cyclopentenone prostaglandin and a metabolite of PGD2. 15-Deoxy-Δ-12,14-prostaglandin J2 is a selective PPARγ (EC₅₀ of 2 µM) and a covalent PPARδ agonist. 15-Deoxy-Δ-12,14-prostaglandin J2 promotes efficient differentiation of C3H10T1/2 fibroblasts to adipocytes with an EC₅₀ of 7 μM ^[1] .

HY-108568S

15-Deoxy-Δ-12,14-prostaglandin J2-d4 15d-PGJ2-d₄; 15-Deoxy-Δ12,14-PGJ2-d₄	PPAR Endogenous Metabolite	Neurological Disease Inflammation/Immunology Cancer
15-Deoxy-Δ-12,14-prostaglandin J2-d₄ is the deuterium labeled 15-Deoxy-Δ-12,14-prostaglandin J2. 15-Deoxy-Δ-12,14-prostaglandin J2 (15d-PGJ2) is a cyclopentenone prostaglandin and a metabolite of PGD2. 15-Deoxy-Δ-12,14-prostaglandin J2 is a selective PPARγ (EC50 of 2 µM) and a covalent PPARδ agonist. 15-Deoxy-Δ-12,14-prostaglandin J2 promotes efficient differentiation of C3H10T1/2 fibroblasts to adipocytes with an EC50 of 7 μM[1][2].

HY-108568R

15-Deoxy-Δ-12,14-prostaglandin J2 (Standard)	PPAR Endogenous Metabolite	Neurological Disease Inflammation/Immunology Cancer
15-Deoxy-Δ-12,14-prostaglandin J2 (Standard) is the analytical standard of 15-Deoxy-Δ-12,14-prostaglandin J2. This product is intended for research and analytical applications. 15-Deoxy-Δ-12,14-prostaglandin J2 (15d-PGJ2) is a cyclopentenone prostaglandin and a metabolite of PGD2. 15-Deoxy-Δ-12,14-prostaglandin J2 is a selective PPARγ (EC₅₀ of 2 μM) and a covalent PPARδ agonist. 15-Deoxy-Δ-12,14-prostaglandin J2 promotes efficient differentiation of C3H10T1/2 fibroblasts to adipocytes with an EC₅₀ of 7 μM ^[1] .

Cat. No.	Product Name	Target	Research Area

HY-P10219

Brevicidine analog 22	Bacterial	Infection Inflammation/Immunology
Brevicidine analog 22 (22) exerts broad spectrum antimicrobial activity and excellent stability (t_1/2 = 40.98 h), with MICs of 2-16 μM for gram-negative and gram-positive bacteria ^[1].

HY-100866B

F1324 acetate	Bcl-2 Family	Cancer
F1324 acetate is a potent, high affinity peptidic inhibitor of B cell lymphoma 6 (BCL6), with an IC₅₀ of 1 nM. F1324 acetate exhibits binding t_1/2 value of 441 s and has strong inhibition activity against BCL6 PPI ^[1].

HY-100866

F1324	Bcl-2 Family	Cancer
F1324 is a potent, high affinity peptidic inhibitor of B cell lymphoma 6 (BCL6) with an IC₅₀ of 1 nM. F1324 exhibits binding t_1/2 value of 441 s and has strong inhibition activity against BCL6 PPI ^[1].

HY-100866A

F1324 TFA	Bcl-2 Family	Cancer
F1324 TFA is a potent, high affinity peptidic inhibitor of B cell lymphoma 6 (BCL6), with an IC₅₀ of 1 nM. F1324 TFA exhibits binding t_1/2 value of 441 s and has strong inhibition activity against BCL6 PPI ^[1].

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-108568

15-Deoxy-Δ-12,14-prostaglandin J2 1 Publications Verification 15d-PGJ2; 15-Deoxy-Δ12,14-PGJ2	Structural Classification Neurological Disease Classification of Application Fields Ketones, Aldehydes, Acids Source classification Endogenous metabolite Inflammation/Immunology Disease Research Fields	PPAR Endogenous Metabolite
15-Deoxy-Δ-12,14-prostaglandin J2 (15d-PGJ2) is a cyclopentenone prostaglandin and a metabolite of PGD2. 15-Deoxy-Δ-12,14-prostaglandin J2 is a selective PPARγ (EC₅₀ of 2 µM) and a covalent PPARδ agonist. 15-Deoxy-Δ-12,14-prostaglandin J2 promotes efficient differentiation of C3H10T1/2 fibroblasts to adipocytes with an EC₅₀ of 7 μM ^[1] .

HY-N12728

Heteroclitin G	Structural Classification Kadsura heteroclita (Roxb.) Craib Source classification Lignans Phenylpropanoids Plants Schisandraceae	Others
Heteroclitin G is a lignan which can be extracted from Dian-Jixueteng. Heteroclitin G (2.0 mg/kg, i.v.) exerts an C_5min of 665.97 ± 29.89 ng/mL and T_1/2z of 5.04 ± 1.84 h ^[1].

HY-N6720

T-2 Triol	Microorganisms Classification of Application Fields Terpenoids Sesquiterpenes Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite
T-2 Triol is a trichothecene mycotoxin derived by the metabolism of T-2 toxin. It is less toxic than T-2 toxin ^[1]. T-2 Triol major metabolites are evaluated in broiler chickens with Half-lives (t_1/2λz), Peak plasma concentrations (C_max) and T_max values of 9.6 mins, 563 ng/ml , 2.5 mins, respectively .

HY-108568R

15-Deoxy-Δ-12,14-prostaglandin J2 (Standard)	Structural Classification Ketones, Aldehydes, Acids Source classification Endogenous metabolite	PPAR Endogenous Metabolite
15-Deoxy-Δ-12,14-prostaglandin J2 (Standard) is the analytical standard of 15-Deoxy-Δ-12,14-prostaglandin J2. This product is intended for research and analytical applications. 15-Deoxy-Δ-12,14-prostaglandin J2 (15d-PGJ2) is a cyclopentenone prostaglandin and a metabolite of PGD2. 15-Deoxy-Δ-12,14-prostaglandin J2 is a selective PPARγ (EC₅₀ of 2 μM) and a covalent PPARδ agonist. 15-Deoxy-Δ-12,14-prostaglandin J2 promotes efficient differentiation of C3H10T1/2 fibroblasts to adipocytes with an EC₅₀ of 7 μM ^[1] .

Cat. No.	Product Name	Chemical Structure

HY-108568S

15-Deoxy-Δ-12,14-prostaglandin J2-d4

15-Deoxy-Δ-12,14-prostaglandin J2-d₄ is the deuterium labeled 15-Deoxy-Δ-12,14-prostaglandin J2. 15-Deoxy-Δ-12,14-prostaglandin J2 (15d-PGJ2) is a cyclopentenone prostaglandin and a metabolite of PGD2. 15-Deoxy-Δ-12,14-prostaglandin J2 is a selective PPARγ (EC50 of 2 µM) and a covalent PPARδ agonist. 15-Deoxy-Δ-12,14-prostaglandin J2 promotes efficient differentiation of C3H10T1/2 fibroblasts to adipocytes with an EC50 of 7 μM[1][2].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

t1/2

Inhibitors & Agonists

Peptides

NaturalProducts

Isotope-Labeled Compounds

Natural
Products